Tevogen Bio Announces Series A-1 Preferred Stock Investment tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The Alumni Cell of All India Institute of Medical Sciences (AIIMS) Bhopal successfully conducted the event, "Path to Success in Competitive Exams," on Saturday. The event catered exclusively to MBBS and BSc Nursing students of AIIMS Bhopal, guiding them towards excelling in competitive exams. The
Share this article
Share this article
METUCHEN, N.J., Jan. 25, 2021 /PRNewswire/ Tevogen Bio today announced it has secured necessary funding from HMP Partners of New Jersey, an investment firm managed by medical doctors, which will allow Tevogen to support all clinical trials of its investigational, potentially curative COVID-19 treatment. Tevogen s Investigational New Drug (IND) application for its proprietary antigen-specific T cell therapy is under review by the U.S. Food and Drug Administration (FDA).
All COVID-19 therapeutics utilized to date have sought to slow the progression of the infection and/or moderate its symptoms. These approaches buy time for the patient s own T cells to activate and respond to the infection, which is the mechanism that the body employs to rid itself of viruses such as the SARS-CoV-2.